New Product Launch Strengthens Bull Case for Twist Bioscience ( TWST)

We recently compiled a list of the 7 Most Promising Gene Editing Stocks According to Analysts. Twist Biosciences Corporation is one of the most promising stocks on our list.

TheFly reported on December 15 that Barclays raised its price target for TWST from $37 to $39 while maintaining an Overweight rating, reflecting confidence in the company’s margin progress and anticipated performance in the life sciences tools sector.

This follows an Overweight initiation on November 3, 2025, by Stephens with a $41 price target, citing Twist Bioscience (NASDAQ: TWST)’s proprietary silicon‑based DNA synthesis platform as a competitive advantage in synthetic biology and research markets.

Strategic product launches have reinforced investor interest. On December 4, 2025, TWST introduced research‑grade Plasmid DNA Preps designed to support pre‑clinical nucleic acid therapeutics research with animal origin‑free and transfection‑grade options, positioning the company as a more integral supplier for biotech and pharmaceutical discovery workflows.

Twist Bioscience (NASDAQ: TWST) is a biotechnology company that has developed a proprietary silicon‑based DNA synthesis platform to “write” DNA, a core enabling technology for modern genetic research and engineering.

While we acknowledge the potential of TWST as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.